Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

Cyclic nucleotide-dependent phosphodiesterases (PDEs) play essential roles in regulating the malaria parasite life cycle, suggesting that they may be promising antimalarial drug targets. PDE inhibitors are used safely to treat a range of noninfectious human disorders. Here, we report three subseries of fast-acting and potent <i>Plasmodium falciparum</i> PDEβ inhibitors that block asexual blood-stage parasite development and that are also active against human clinical isolates. Two of the inhibitor subseries also have potent transmission-blocking activity by targeting PDEs expressed during sexual parasite development. In vitro drug selection experiments generated parasites with moderately reduced susceptibility to the inhibitors. Whole-genome sequencing of these parasites detected no mutations in PDEβ but rather mutations in downstream effectors: either the catalytic or regulatory subunits of cyclic adenosine monophosphate-dependent protein kinase (PKA) or in the 3-phosphoinositide-dependent protein kinase that is required for PKA activation. Several properties of these <i>P. falciparum</i> PDE inhibitor series make them attractive for further progression through the antimalarial drug discovery pipeline.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2024-12-06
DOI
https://doi.org/10.1126/sciadv.adq1383
Citations
3
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
1.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

Roland A. Cooper, Koen J. Dechering, Paula Josefina Gómez, Luke Brandner-Garrod et al.
3 citations
Science Advances
Malaria Research and Control
1.63
article

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

Roland A. Cooper, Koen J. Dechering, Paula Josefina Gómez, Luke Brandner-Garrod, Mark Palmer, Lindsay B. Stewart, Mark Gardner, John Okombo, Youri M. van Nuland, Alan Brown, Anna Y. Burkhard, Kyra A. Schindler, Kate J. Fairhurst, Heekuk Park, Mojca Kristan, Christian Flueck, Jennifer L. Small-Saunders, Tanya Parkinson, Dhélio B. Pereira, Janette Reader, Tomas Yeo, Donelly A. van Schalkwyk, Yang Zheng, Anna Caroline Campos Aguiar, Emilia Mańko, Eloise M. Walker, Anumeha Gupta, David A. Fidock, Sunil Kumar Narwal, James Duffy, Mariëtte van der Watt, Philip J. Rosenthal, Patrick K. Tumwebaze, Rafael V. C. Guido, David A. Baker, Lyn‐Marié Birkholtz, Laura Drought, Rob Leurs, Jeremy N. Burrows, Anne‐Catrin Uhlemann, Talia S. Bloxham, Avnish Patel, Geert-Jan Sterk, Harry Pollard, Joshua A. Rey, Samuel L. Nosbya, Ryan Walker-Gray
article en
3 citations

Abstract

Cyclic nucleotide-dependent phosphodiesterases (PDEs) play essential roles in regulating the malaria parasite life cycle, suggesting that they may be promising antimalarial drug targets. PDE inhibitors are used safely to treat a range of noninfectious human disorders. Here, we report three subseries of fast-acting and potent <i>Plasmodium falciparum</i> PDEβ inhibitors that block asexual blood-stage parasite development and that are also active against human clinical isolates. Two of the inhibitor subseries also have potent transmission-blocking activity by targeting PDEs expressed during sexual parasite development. In vitro drug selection experiments generated parasites with moderately reduced susceptibility to the inhibitors. Whole-genome sequencing of these parasites detected no mutations in PDEβ but rather mutations in downstream effectors: either the catalytic or regulatory subunits of cyclic adenosine monophosphate-dependent protein kinase (PKA) or in the 3-phosphoinositide-dependent protein kinase that is required for PKA activation. Several properties of these <i>P. falciparum</i> PDE inhibitor series make them attractive for further progression through the antimalarial drug discovery pipeline.

Science AdvancesVol. 10(49)
Dominican University of California (US), Universidade de São Paulo (BR), University of California, San Francisco (US), Liverpool School of Tropical Medicine (GB), Columbia University Irving Medical Center (US), London School of Hygiene & Tropical Medicine (GB), Infectious Diseases Research Collaboration (UG), TropIQ Health Sciences (NL), The Research Network (GB), Medicines for Malaria Venture (CH), University of Pretoria (ZA), Vrije Universiteit Amsterdam (NL), Universidade Federal de São Paulo (BR)
Francis Crick Institute
Zero hunger
Openalex Percentile: Top 15%
Malaria Research and Control
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.